Welcome to our dedicated page for Dare Bioscience news (Ticker: DARE), a resource for investors and traders seeking the latest updates and insights on Dare Bioscience stock.
Dare Bioscience Inc (NASDAQ: DARE) is a clinical-stage biopharmaceutical leader advancing innovative therapies for women’s reproductive and sexual health. This dedicated news hub provides investors and healthcare professionals with essential updates on clinical trial progress, regulatory milestones, and strategic partnerships.
Track the latest developments across DARE’s pipeline of non-hormonal contraceptives, sexual health treatments, and cervical health solutions. Our curated news collection includes updates on FDA submissions, trial results for candidates like Ovaprene® and Sildenafil Cream 3.6%, and collaborations advancing women’s healthcare innovation.
Key focus areas include progress toward addressing unmet needs in bacterial vaginosis treatment, female sexual arousal disorder (FSAD), and HPV-related cervical conditions. Bookmark this page for real-time access to earnings announcements, research publications, and licensing agreements that shape DARE’s position in the biopharma sector.
Daré Bioscience, Inc. (NASDAQ: DARE) announced the initiation of a Phase 1 clinical study for its Sildenafil Cream, a potential treatment for female sexual arousal disorder (FSAD). The study aims to assess the pharmacodynamic and pharmacokinetic properties of the cream using thermography, with the goal of collecting quantitative data to complement patient-reported outcomes from the ongoing Phase 2b RESPOND study. This innovative cream formulation is designed to increase blood flow to genital tissues, addressing issues similar to erectile dysfunction in men. Approximately 15 women will be enrolled, and completion is planned for 2023. Topline data for the Phase 2b study is anticipated in Q2 2023, providing critical insights into the product's efficacy.
Daré Bioscience (NASDAQ: DARE) has announced that its Chief Scientific Officer, David Friend, Ph.D., will present at the Global Pharma & Drug Delivery Summit 2023 in Frankfurt, Germany, scheduled for April 24-26, 2023. His presentation will focus on the Safety and Pharmacokinetic Assessment of Ovaprene, a once-monthly non-hormonal vaginal contraceptive.
Ovaprene is designed to provide a hormone-free contraceptive option through a unique knitted polymer barrier that hinders sperm motility. The company recently received an FDA-approved Investigational Device Exemption to conduct a pivotal clinical study to evaluate Ovaprene’s effectiveness and safety over 12 months. This research is essential for a future Premarket Approval submission to the FDA, and subject recruitment is anticipated to begin in mid-2023.
FAQ
What is the current stock price of Dare Bioscience (DARE)?
What is the market cap of Dare Bioscience (DARE)?
